Istesso Limited (“Istesso’’) today announces that it has closed a £6 million investment round. The new money will enable Istesso to explore new indications for its Phase 2 molecule, MBS2320, and further develop its pre-clinical programmes.
Participants in the round include new investors Parkwalk Advisors, the UK’s leading EIS investor in technology companies, and Puhua Capital, a Chinese venture capital firm with a strong presence in the healthcare sector, along with existing shareholder IP Group plc.
MBS2320 is currently being evaluated in a Phase 2a clinical trial in rheumatoid arthritis (RA), from which data are expected in 2019. MBS2320 is a first-in-class immunometabolism agent which works by reprogramming cellular metabolism and has potential applications in conditions beyond RA, such as ulcerative colitis and cancer. Istesso has additional immunometabolism programmes in pre-clinical development targeted at RA and multiple sclerosis.
For further information, please contact:
Dr Sam Williams, CEO +44 207 444 0066
Notes to Editors
Istesso is a drug discovery and development company in the field of immunometabolism. Istesso’s pipeline of discovery and clinical assets work by reprogramming cellular metabolism and have applications in autoimmune and inflammatory conditions such as rheumatoid arthritis and multiple sclerosis, as well as cancer. For more information please visit www.istesso.co.uk.